Veracyte is evolving into a self-funded cancer diagnostic platform, leveraging clinical evidence. Click here to read more ...

Veracyte’s core tests are Decipher and Afirma. Both of these tests are producing double-digit growth with improving margins.

Veracyte (NASDAQ:VCYT) reported second-quarter 2026 revenue growth of 15% and raised its full-year revenue outlook, while highlighting the launches of its Prosigna LDT breast cancer test and TrueMRD ...

Veracyte swung to GAAP profitability while crushing EPS estimates by 25% in Q2, powered by 20% growth in Decipher Prostate ...

Earnings call Veracyte delivered a milestone Q2 2026 with total revenue of $150.3M, up 15% YoY, and adjusted EBITDA of $44M (29.2% margin). Management raised full-year revenue guidance to $590–$596M ...

Grew total revenue to $150.3 million and testing revenue to $145.7 million, representing increases of 15% and 19%year-over-year, ...

Meridian Funds, managed by ArrowMark Partners, released its second-quarter 2026 investor letter for “Meridian Small Cap ...

(Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will be participating in the following investor conferences: Live audio webcasts of the company’s presentations will be ...

Prostate cancer is projected to be the most commonly diagnosed cancer among men in the United States next year, and the ...

The NHS is inviting 500,000 men with prostate cancer histories to join Prostate Progress, a research programme focused on ...

Pre-biopsy MRI is standard outside the U.S., but the latest data show such scans were done in only about a third of U.S.

Focal therapy is as effective as surgery and radiotherapy for localized prostate cancer while significantly reducing the risk of urinary and sexual side effects.